Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 21 studies | 66% ± 19% | |
peripheral blood | 21 studies | 86% ± 9% | |
brain | 18 studies | 35% ± 19% | |
intestine | 13 studies | 63% ± 21% | |
kidney | 9 studies | 58% ± 20% | |
eye | 9 studies | 42% ± 22% | |
liver | 8 studies | 62% ± 24% | |
bone marrow | 6 studies | 74% ± 18% | |
lymph node | 6 studies | 88% ± 6% | |
pancreas | 5 studies | 69% ± 12% | |
uterus | 5 studies | 79% ± 14% | |
adipose | 5 studies | 39% ± 21% | |
prostate | 5 studies | 63% ± 27% | |
breast | 5 studies | 71% ± 24% | |
placenta | 4 studies | 74% ± 14% | |
heart | 4 studies | 31% ± 10% | |
esophagus | 4 studies | 55% ± 29% | |
skin | 4 studies | 54% ± 19% | |
adrenal gland | 3 studies | 68% ± 20% | |
thymus | 3 studies | 80% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 100% | 44313.08 | 966 / 966 | 100% | 701.54 | 527 / 527 |
prostate | 100% | 42524.66 | 245 / 245 | 100% | 628.95 | 502 / 502 |
stomach | 100% | 33485.25 | 359 / 359 | 100% | 722.39 | 286 / 286 |
esophagus | 100% | 57418.92 | 1444 / 1445 | 100% | 872.16 | 183 / 183 |
ovary | 100% | 58764.31 | 180 / 180 | 100% | 663.07 | 429 / 430 |
bladder | 100% | 52036.48 | 21 / 21 | 100% | 941.76 | 502 / 504 |
lung | 100% | 42604.99 | 576 / 578 | 100% | 611.14 | 1151 / 1155 |
breast | 100% | 50357.20 | 459 / 459 | 99% | 655.37 | 1109 / 1118 |
uterus | 100% | 40479.26 | 170 / 170 | 99% | 536.54 | 454 / 459 |
skin | 100% | 62080.08 | 1809 / 1809 | 99% | 559.35 | 465 / 472 |
thymus | 100% | 28671.74 | 652 / 653 | 98% | 295.32 | 592 / 605 |
pancreas | 99% | 31271.72 | 325 / 328 | 97% | 424.58 | 173 / 178 |
kidney | 100% | 21704.07 | 89 / 89 | 86% | 209.48 | 779 / 901 |
liver | 93% | 13938.27 | 210 / 226 | 84% | 261.33 | 340 / 406 |
adrenal gland | 100% | 27133.79 | 258 / 258 | 66% | 126.25 | 151 / 230 |
brain | 68% | 8382.03 | 1784 / 2642 | 91% | 217.65 | 644 / 705 |
adipose | 100% | 52884.09 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 898.15 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 608.70 | 29 / 29 |
spleen | 100% | 39125.41 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 499.86 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 882.37 | 1 / 1 |
blood vessel | 100% | 35620.74 | 1334 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 58208.58 | 918 / 929 | 0% | 0 | 0 / 0 |
heart | 77% | 10477.10 | 662 / 861 | 0% | 0 | 0 / 0 |
muscle | 63% | 8049.80 | 503 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000767 | Biological process | positive regulation of cytoplasmic translation |
GO_0060213 | Biological process | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening |
GO_0048255 | Biological process | mRNA stabilization |
GO_0000184 | Biological process | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
GO_0045070 | Biological process | positive regulation of viral genome replication |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_1900153 | Biological process | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
GO_2000623 | Biological process | negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
GO_0031047 | Biological process | regulatory ncRNA-mediated gene silencing |
GO_0070934 | Biological process | CRD-mediated mRNA stabilization |
GO_1900152 | Biological process | negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
GO_0016020 | Cellular component | membrane |
GO_0036464 | Cellular component | cytoplasmic ribonucleoprotein granule |
GO_0070062 | Cellular component | extracellular exosome |
GO_0106002 | Cellular component | mCRD-mediated mRNA stability complex |
GO_0031252 | Cellular component | cell leading edge |
GO_0005925 | Cellular component | focal adhesion |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0030027 | Cellular component | lamellipodium |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0005634 | Cellular component | nucleus |
GO_0008143 | Molecular function | poly(A) binding |
GO_0008494 | Molecular function | translation activator activity |
GO_0003729 | Molecular function | mRNA binding |
GO_0008266 | Molecular function | poly(U) RNA binding |
GO_0003723 | Molecular function | RNA binding |
GO_0003730 | Molecular function | mRNA 3'-UTR binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PABPC1 |
Protein name | Polyadenylate-binding protein (PABP) Polyadenylate-binding protein 1 (PABP-1) (Poly(A)-binding protein 1) Polyadenylate-binding protein 1 Poly(A) binding protein cytoplasmic 1 |
Synonyms | PAB1 PABP PABPC2 hCG_15683 PABP1 |
Description | FUNCTION: Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability . Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2 . Can probably bind to cytoplasmic RNA sequences other than poly(A) in vivo. Binds to N6-methyladenosine (m6A)-containing mRNAs and contributes to MYC stability by binding to m6A-containing MYC mRNAs . Involved in translationally coupled mRNA turnover . Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain . Involved in regulation of nonsense-mediated decay (NMD) of mRNAs containing premature stop codons; for the recognition of premature termination codons (PTC) and initiation of NMD a competitive interaction between UPF1 and PABPC1 with the ribosome-bound release factors is proposed . By binding to long poly(A) tails, may protect them from uridylation by ZCCHC6/ZCCHC11 and hence contribute to mRNA stability . .; FUNCTION: (Microbial infection) Positively regulates the replication of dengue virus (DENV). . FUNCTION: Binds the poly(A) tail of mRNA. . FUNCTION: Binds the poly(A) tail of mRNA. . FUNCTION: Binds the poly(A) tail of mRNA. . FUNCTION: Binds the poly(A) tail of mRNA. . FUNCTION: Binds the poly(A) tail of mRNA. . FUNCTION: Binds the poly(A) tail of mRNA. . FUNCTION: Binds the poly(A) tail of mRNA. . |
Accessions | ENST00000519100.6 ENST00000517990.5 H0YB75 ENST00000520868.5 A0A7I2V3J9 H0YAS7 E7ERJ7 ENST00000518293.5 E5RJB9 ENST00000678954.1 A0A7I2YQ90 ENST00000677787.1 E5RFD8 E5RHG7 H0YAS6 ENST00000518196.5 H0YB86 ENST00000676662.1 E5RGH3 ENST00000522387.5 ENST00000517403.5 E5RH24 ENST00000677765.1 ENST00000522720 ENST00000520142.2 [P11940-1] H0YC10 H0YAW6 ENST00000520142 A0A7I2V4N4 ENST00000520804.2 [P11940-1] ENST00000521865 A0A7I2YQ88 ENST00000523636.5 ENST00000519004.5 ENST00000523555.6 [P11940-1] ENST00000521865.6 [P11940-1] ENST00000523555 A0A087WTT1 H0YAR2 H0YAP2 ENST00000519622.5 ENST00000522658 H0YBN4 ENST00000677140.1 E5RJM8 ENST00000522658.6 [P11940-1] ENST00000677478.1 ENST00000318607.10 [P11940-1] ENST00000520804 ENST00000610907.2 ENST00000519363.1 A0A7I2YQE4 ENST00000677380.1 E7EQV3 ENST00000522720.2 [P11940-1] ENST00000679197.1 P11940 ENST00000521067.1 A0A7I2V649 E5RGC4 |